SK228 inhibits the growth of 4T1-Luc xenografts and consequently delays cancer cell metastasis via reversal of EMT process and miR-200c/ZEB1/E-cadherin signaling pathway.

<p>(<b>A</b>) BALB/c mice bearing the established 4T1-Luc tumors (50 mm³) are treated with SK228 (12.5 mg/kg/mouse/week) via intraperitoneal injection on the first 3 days in the first week, then two shots on day 1 and day 4 at a dose of 6.25 mg/kg/week for another 3 weeks (final dose = 50 mg/kg/mouse), or vehicle (30% PEG400+70% PBS) control. The results of spontaneous metastasis assays show that SK228 treatment delays cancer cell metastasis in animal models. (B) The tumor size indicated in the graph represents the measurement of the primary tumor only. Tumor volumes, measured every other day until day 28, are expressed as mean ± SD; *P = 0.045. (C) The average body weight between vehicle and SK228 groups is not significantly different.